Business
Announces two new biopharmaceutical contracts
Announces two new biopharmaceutical contracts.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 8593W IXICO plc 24 April 2019 \n\n24 April 2019\nIXICO plc\n(\"IXICO\" or the \"Company\")\n \nIXICO announces two new biopharmaceutical contracts \n \nProviding specialist imaging clinical trials services for rare neurological diseases\n \nIXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces that it has signed contracts with two biopharmaceutical companies to provide its technology-enabled imaging services to support an early phase study in Huntington's Disease (HD) and a phase 3 study in another rare neurological disease. The contracts are both the first to be signed with these clients. \n \nAs the selected imaging analysis partner for these studies, IXICO will utilise its data analytics expertise, developed over many years of working in the field, to provide critical insights which will support the evaluation of drug safety and efficacy. Study planning and site set-up activities are due to start imminently, contributing revenues for 2019 and into future periods. \nThe HD contract has a total value of approximately £2.0 million, which will be delivered over a seven-year term. HD is a rare genetic neurodegenerative disorder that affects movement, cognition and behaviour. This is an area of significant unmet medical need as there are currently no effective marketed treatments.\nWith 12 years' experience in HD studies and data analytics, IXICO is an established industry leader having supported early observational studies led by academic centres in Europe and North America, which characterised the progression of the disease. Since then IXICO has been successful in providing its clinical trial services to pharmaceutical and biopharmaceutical companies working in this important area of clinical development.\nThe second contract is with a company undergoing a phase 3 study in another rare neurological disease. This is initially a start-up agreement to enable IXICO to begin to deploy its services to the study which anticipates recruiting patients in June 2019. A contract for the full study is expected to be completed in the coming months. \n \nGiulio Cerroni, Chief Executive Officer of IXICO, commented:\n \n\"Today's announcement follows multiple recent new contracts in Huntington's disease and builds on IXICO's strong tr...